Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

10 Oct 2007 07:01

Sopheon PLC10 October 2007 Embargoed Release: 07:00hrs Wednesday 10 October 2007 Sopheon Plc ('Sopheon') Leading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System The University Medical Center Utrecht Enhances Processes and Strengthens Position in Rapidly Expanding Trials Outsourcing Market Sopheon, the international software and services company, announced today thatthe University Medical Center (UMC) Utrecht, represented by its division theJulius Center, has selected Sopheon's Accolade product life cycle managementsystem to support its processes for conducting trials. Julius' research programis comprised of initiatives sponsored by leading pharmaceutical companies,universities and the government, including clinical investigations that involveother UMC divisions. Pharmaceutical companies are expected to increase spending for outsourced R&Dservices by almost 15% annually for the next five years. The core of thistrend is the outsourcing of clinical development, which more and morepharmaceutical executives see as a way to reduce costs and increase efficiency.The outsourced model also makes it possible to complete trials more quickly.The global growth in demand for outsourced clinical trial services is fuelingnew levels of business opportunity for independent research operations such asthe Julius Center. Julius is a particularly attractive alternative because ithas unique competencies in the management of complex, global clinical trialsinvolving multiple medical centers. More than 2,000 clinical trials are completed across UMC Utrecht each year, andJulius conducts or oversees a large portion of these investigations. Theadoption of Accolade will help the organization handle a steadily growing volumeof trial activity. Accolade provides an automated process structure that willenable the Center's research and program management staff to accelerate trialpreparation and execution. The system's data protection and managementcapabilities will contribute to ensuring trial security and quality, andfacilitate more efficient collaboration among researchers. Implementation ofthe system will also support compliance with European GCP (Good ClinicalPractice) directives for clinical trial execution. "As acceptance of the outsourced model for clinical trials management hasincreased among public and private organizations, our project pipeline hasbecome deeper and more complicated," said Robert Veen, data management managerfor the Julius Center. "Our deployment of Accolade has allowed us to takeproject data previously recorded and stored on isolated tools like spreadsheets,and consolidate them in a single, easily accessed repository. The flexibilityof the Accolade system, reflected in the fact that we can configure it on ourown, provides us with a platform that can accommodate multiple processes and anearly limitless range of specific process requirements. Accolade gives usconfidence that our trials will be executed consistently and with the kind ofrigorous quality control that will ensure the accuracy and reliability of theiroutcomes. Sopheon's solution will allow us to take the professionalization ofour research processes to a whole new level." "The University Medical Center Utrecht is an international symbol of excellencein scientific research and education," said Huub Rutten, Sopheon's vicepresident of research and development. "Their clinical trial operations are,like Sopheon and Accolade, focused on helping organizations get better productsto market faster. They have built their success on quality performance and anabiding commitment to the pursuit of best practices. We are proud to be able tocontribute even indirectly to the invention of the important new medicines andtreatments that result from their efforts." - Ends - Accolade(R) is a registered trademark of Sopheon plc. All other trademarks and registered trademarks are the sole property of their respective owners. About Julius Center Founded in 1996, the Julius Center for Health Sciences and Primary Care is partof the University Medical Center Utrecht. It carries out scientific research,provides education, and offers expertise and facilities in the area of clinicalhealth sciences, specializing in epidemiology, public health, general practice,nursing, dietary science, and medical technology assessment. The center has aleading and acquisitive position in the enlargement and dissemination ofknowledge, especially in the field of health sciences. This is done by means ofgroundbreaking research and by the provision of courses for researchers andclinicians. For more information, please visit the research section atwww.umcutrecht.nl About Sopheon Sopheon (LSE:SPE) is an international provider of software and services thathelp organizations improve the business impact of product innovation. Sopheon'sAccolade system automates and governs the innovation process, enabling companiesto increase revenue and profits from new products. Sopheon is listed on the AIMMarket of the London Stock Exchange and on the Euronext in the Netherlands. Formore information, please visit www.sopheon.com For further information contact: Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735Arif Karimjee, CFOAndrew Tan Hansard Tel : + 44 (0) 207 245 1100 + 44 (0) 7957 203 685Floor van Maaren Citigate First Financial Tel : + 31 (0) 205 754 010 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.